Vor Biopharma (NASDAQ:VOR) Trading Down 6.2% – What’s Next?

Vor Biopharma Inc. (NASDAQ:VOR) shares were down 6.2% during trading on Monday . The stock traded as low as $18.05 and last traded at $17.9550. Approximately 386,582 shares were traded during mid-day trading, a decline of 65% from the average session volume of 1,104,882 shares. The stock had previously closed at $19.14.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Wells Fargo & Company assumed coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target on the stock. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wedbush increased their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Price Performance

The firm has a 50-day moving average of $15.72 and a 200-day moving average of $14.89.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. On average, equities analysts anticipate that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Activity

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares in the company, valued at $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 1,002,903 shares of company stock worth $16,093,191. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma during the 4th quarter valued at approximately $36,000. Goldman Sachs Group Inc. lifted its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in Vor Biopharma in the 2nd quarter worth approximately $66,000. Chung Wu Investment Group LLC bought a new position in Vor Biopharma in the 4th quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma during the 4th quarter valued at approximately $134,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).